Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
  • 9 Jul, 2024

Biospace features Tallac Therapeutics as an antibody-drug conjugate (ADC) drug developer

  • 24 Jun, 2024

Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs).

  • 10 Apr, 2024

Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

  • 3 Nov, 2023

Tallac Presents First Clinical Data for TAC-001 at SITC 2023

  • 27 Sep, 2023

Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

  • 11 Nov, 2022

Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting

  • 28 Jul, 2022

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

  • 19 May, 2022

Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors

  • 21 Oct, 2021

Tallac SITC 2021 Presentation

  • 15 Apr, 2021

Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

  • 12 Apr, 2021

Tallac AACR 2021 Presentation

  • 12 Mar, 2021

AACR 2021 presentation on preclinical data for TAC-001

  • 4 Mar, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

  • 1 Dec, 2020

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

  • 5 Nov, 2020

SITC 2020 Presentation

view more
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2025 Tallac Therapeutics, Inc. All Rights Reserved.